{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:29:08Z","timestamp":1793694548417,"version":"4.5.1"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270760"],"award-info":[{"award-number":["32270760"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.phrs.2026.108444","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:08:30Z","timestamp":1789571310000},"page":"108444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Gut microbiota modulates nonalcoholic fatty liver disease (NAFLD) progression via regulation of gluconeogenesis: mechanisms and translational research"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7988-4237","authenticated-orcid":false,"given":"WeiZhou","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunTao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZiQian","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiQuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhouHang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuiLong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QiPeng","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShangZe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108444_bib2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut-liver axis in liver disease","volume":"67","author":"Wiest","year":"2017","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/hep.30848","article-title":"Changing NAFLD Epidemiology in China","volume":"70","author":"Lee","year":"2019","journal-title":"Hepatology"},{"issue":"648","key":"10.1016\/j.phrs.2026.108444_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk0855","article-title":"Risk assessment with gut microbiome and metabolite markers in NAFLD development","volume":"14","author":"Leung","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr. Obes. Rep."},{"issue":"7","key":"10.1016\/j.phrs.2026.108444_bib6","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.phrs.2026.108444_bib7","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.phrs.2026.108444_bib8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.phrs.2026.108444_bib9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4254\/wjh.v7.i3.559","article-title":"Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease","volume":"7","author":"Ferolla","year":"2015","journal-title":"World J. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108444_bib11","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.phrs.2026.108444_bib12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.phrs.2026.108444_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcmgh.2015.05.006","article-title":"Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences","volume":"1","author":"Joshi-Barve","year":"2015","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108444_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cell.2013.12.016","article-title":"Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits","volume":"156","author":"De Vadder","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108444_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2431-13-40","article-title":"Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets","volume":"13","author":"Giorgio","year":"2013","journal-title":"BMC Pediatr."},{"issue":"12","key":"10.1016\/j.phrs.2026.108444_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e12294","article-title":"Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae","volume":"8","author":"Onyango","year":"2022","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41575-022-00707-6","article-title":"Intestinal gluconeogenesis: metabolic benefits make sense in the light of evolution","volume":"20","author":"Gautier-Stein","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108444_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1152\/physiolgenomics.00056.2004","article-title":"Fructose-responsive genes in the small intestine of neonatal rats","volume":"18","author":"Cui","year":"2004","journal-title":"Physiol. Genom."},{"issue":"5","key":"10.1016\/j.phrs.2026.108444_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cmet.2005.09.010","article-title":"Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein","volume":"2","author":"Mithieux","year":"2005","journal-title":"Cell. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib21","doi-asserted-by":"crossref","first-page":"832S","DOI":"10.3945\/ajcn.2009.27462V","article-title":"Activation of the gut-brain axis by dietary glutamate and physiologic significance in energy homeostasis","volume":"90","author":"Kondoh","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"issue":"6","key":"10.1016\/j.phrs.2026.108444_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25063481","article-title":"Anaerobutyricum soehngenii reduces hepatic lipogenic pathways and increases intestinal gluconeogenic gene expression in metabolic-dysfunction-associated steatotic liver disease (MASLD) mice","volume":"25","author":"Mak","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108444_bib23","article-title":"Microbiome and metabolomics reveal the effect of gut microbiota on liver regeneration of fatty liver disease","volume":"111","author":"Hu","year":"2024","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib24","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","article-title":"Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes","volume":"160","author":"Perry","year":"2015","journal-title":"Cell"},{"issue":"2041-1723","key":"10.1016\/j.phrs.2026.108444_bib26","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1038\/ncomms6190","article-title":"Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors","volume":"5","author":"Haeusler","year":"2014","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2026.108444_bib27","first-page":"2464","article-title":"Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism","volume":"116","author":"Matsumoto","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"17","key":"10.1016\/j.phrs.2026.108444_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161282","article-title":"Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models","volume":"8","author":"Matsukawa","year":"2023","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.phrs.2026.108444_bib29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2017.09.001","article-title":"Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders","volume":"23","author":"Pinkosky","year":"2017","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108444_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell. Metab."},{"issue":"20","key":"10.1016\/j.phrs.2026.108444_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205037","article-title":"Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products","volume":"20","author":"Fernando","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11-12","key":"10.1016\/j.phrs.2026.108444_bib32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1055\/s-2002-38248","article-title":"Insulin decreases human adiponectin plasma levels","volume":"34","author":"M\u00f6hlig","year":"2002","journal-title":"Horm. Metab. Res."},{"issue":"10","key":"10.1016\/j.phrs.2026.108444_bib33","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1016\/j.bbadis.2018.08.012","article-title":"Adiponectin inhibits hepatic stellate cell activation by targeting the PTEN\/AKT pathway","volume":"1864","author":"Kumar","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-alpha or adiponectin?","volume":"40","author":"Hui","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1186\/s12967-024-05621-w","article-title":"VEGFB ameliorates insulin resistance in NAFLD via the PI3K\/AKT signal pathway","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.phrs.2026.108444_bib36","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1136\/gutjnl-2019-319745","article-title":"Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease","volume":"69","author":"Vily-Petit","year":"2020","journal-title":"Gut"},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108444_bib37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cell.2013.12.016","article-title":"Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits","volume":"156","author":"De Vadder","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.diabet.2010.05.001","article-title":"Hypothalamic integration of portal glucose signals and control of food intake and insulin sensitivity","volume":"36","author":"Delaere","year":"2010","journal-title":"Diabetes Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100106","article-title":"Metformin-mechanisms of its glycemia-reducing effect","volume":"78","author":"Drewe","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/nmo.12508","article-title":"Vasoactive intestinal peptide is a local mediator in a gut-brain neural axis activating intestinal gluconeogenesis","volume":"27","author":"De Vadder","year":"2015","journal-title":"Neurogastroenterol. Motil."},{"issue":"2","key":"10.1016\/j.phrs.2026.108444_bib41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2012.05.039","article-title":"Mu-opioid receptors and dietary protein stimulate a gut-brain neural circuitry limiting food intake","volume":"150","author":"Duraffourd","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.phrs.2026.108444_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/db11-1019","article-title":"Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2","volume":"61","author":"Tolhurst","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2026.108444_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.07.022","article-title":"Propionate suppresses hepatic gluconeogenesis via GPR43\/AMPK signaling pathway","volume":"672","author":"Yoshida","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/0004563218817798","article-title":"Bile acids and the metabolic syndrome","volume":"56","author":"McGlone","year":"2019","journal-title":"Ann. Clin. Biochem."},{"issue":"6","key":"10.1016\/j.phrs.2026.108444_bib45","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1\u03b1 pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib47","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.phrs.2026.108444_bib48","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108444_bib49","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2026.108444_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7659509","article-title":"Role of bile acids in dysbiosis and treatment of nonalcoholic fatty liver disease","volume":"2019","author":"Wang","year":"2019","journal-title":"Mediat. Inflamm."},{"issue":"12","key":"10.1016\/j.phrs.2026.108444_bib51","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.3382\/ps\/pez483","article-title":"Effects of dietary inulin supplementation on the composition and dynamics of cecal microbiota and growth-related parameters in broiler chickens","volume":"98","author":"Xia","year":"2019","journal-title":"Poult. Sci."},{"issue":". 1","key":"10.1016\/j.phrs.2026.108444_bib52","first-page":"s3","article-title":"Bile Acid Physiology","volume":"16","author":"Di Ciaula","year":"2017","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.phrs.2026.108444_bib53","article-title":"From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108444_bib54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.28572","article-title":"Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach","volume":"65","author":"Del Chierico","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108444_bib55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib56","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2026.108444_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115457","article-title":"Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis","volume":"296","author":"Ye","year":"2022","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib58","doi-asserted-by":"crossref","first-page":"R34","DOI":"10.1152\/ajpregu.00147.2013","article-title":"High-fat diet induces site-specific unresponsiveness to LPS-stimulated STAT3 activation in the hypothalamus","volume":"306","author":"de Carvalho Borges","year":"2014","journal-title":"Am. J. Physiol. -Regul. Integr. Comp. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib59","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1039\/C8FO02265H","article-title":"Dietary inulin alleviates diverse stages of type 2 diabetes mellitus via anti-inflammation and modulating gut microbiota in db\/db mice","volume":"10","author":"Li","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.phrs.2026.108444_bib60","article-title":"Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats","volume":"6","author":"Zhang","year":"2018","journal-title":"PeerJ"},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib61","article-title":"[Shenling Baizhu Powder alleviates chronic inflammation to prevent type 2 diabetes of ZDF rats via intestinal flora]","volume":"47","author":"Zhang","year":"2022","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib62","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib63","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/gutjnl-2020-322753","article-title":"Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function","volume":"70","author":"Frost","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib64","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108444_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2020.108365","article-title":"The modulation of Luffa cylindrica (L.) Roem supplementation on gene expression and amino acid profiles in liver for alleviating hepatic steatosis via gut microbiota in high-fat diet-fed mice: insight from hepatic transcriptome analysis","volume":"80","author":"Zhang","year":"2020","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.phrs.2026.108444_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodres.2023.112723","article-title":"Improvement of energy metabolism associated with NUTRIOSE\u00ae soluble fiber, a dietary ingredient exhibiting prebiotic properties, requires intestinal gluconeogenesis","volume":"167","author":"Vily-Petit","year":"2023","journal-title":"Food Res. Int."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib67","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jnutbio.2012.01.014","article-title":"Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model","volume":"24","author":"Wagnerberger","year":"2012","journal-title":"J. Nutr. Biochem."},{"issue":"5","key":"10.1016\/j.phrs.2026.108444_bib68","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/1462-2920.13181","article-title":"Beneficial metabolic effects of selected probiotics on diet-induced obesity and insulin resistance in mice are associated with improvement of dysbiotic gut microbiota","volume":"18","author":"Alard","year":"2016","journal-title":"Environ. Microbiol."},{"issue":"13","key":"10.1016\/j.phrs.2026.108444_bib69","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1039\/D4FO01231C","article-title":"Comparative analysis of pectin and prebiotics on human microbiota modulation in early life stages and adults","volume":"15","author":"Donadio","year":"2024","journal-title":"Food Funct."},{"issue":"19","key":"10.1016\/j.phrs.2026.108444_bib70","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean diet and nonalcoholic fatty liver disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib71","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2223339","article-title":"Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis","volume":"15","author":"G\u00f3mez-P\u00e9rez","year":"2023","journal-title":"Gut Microbes"},{"issue":"7","key":"10.1016\/j.phrs.2026.108444_bib72","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108444_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/nu12082340","article-title":"The relationship between choline bioavailability from diet, intestinal microbiota composition, and its modulation of human diseases","volume":"12","author":"Arias","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2026.108444_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.885039","article-title":"Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2\/NLRP3 pathway","volume":"13","author":"Yue","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.phrs.2026.108444_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2024.1383801","article-title":"A study on the treatment effects of Crataegus pinnatifida polysaccharide on non-alcoholic fatty liver in mice by modulating gut microbiota","volume":"11","author":"Hao","year":"2024","journal-title":"Front. Vet. Sci."},{"issue":"12","key":"10.1016\/j.phrs.2026.108444_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/md19120699","article-title":"Soluble polysaccharide derived from laminaria japonica attenuates obesity-related nonalcoholic fatty liver disease associated with gut microbiota regulation","volume":"19","author":"Zhang","year":"2021","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.phrs.2026.108444_bib77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijbiomac.2021.12.036","article-title":"MDG, an Ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila","volume":"196","author":"Zhang","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.phrs.2026.108444_bib78","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ijbiomac.2019.09.007","article-title":"MDG-1, an Ophiopogon polysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis","volume":"141","author":"Wang","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.phrs.2026.108444_bib79","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ijbiomac.2021.05.066","article-title":"Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation","volume":"183","author":"Gao","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.phrs.2026.108444_bib80","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ijbiomac.2019.09.002","article-title":"Protective effects of polysaccharides on hepatic injury: A review","volume":"141","author":"Yuan","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.phrs.2026.108444_bib81","article-title":"\u03b1-D-1,3-glucan from Radix Puerariae thomsonii improves NAFLD by regulating the intestinal flora and metabolites","volume":"299","author":"Li","year":"2022","journal-title":"Carbohydr. Polym."},{"issue":"14","key":"10.1016\/j.phrs.2026.108444_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202300453","article-title":"Exploring the regulatory effect of tegillarca granosa polysaccharide on high-fat diet-induced non-alcoholic fatty liver disease in mice based on intestinal flora","volume":"68","author":"Yang","year":"2024","journal-title":"Mol. Nutr. Food Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108444_bib83","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jhep.2008.01.035","article-title":"Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin","volume":"48","author":"Bergheim","year":"2008","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108444_bib84","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3748\/wjg.14.313","article-title":"Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats","volume":"14","author":"Wu","year":"2008","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"issue":"25","key":"10.1016\/j.phrs.2026.108444_bib86","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3748\/wjg.v23.i25.4491","article-title":"Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation","volume":"23","author":"Ponziani","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108444_bib87","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2026.108444_bib88","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.phrs.2026.108444_bib89","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1111\/jgh.15071","article-title":"Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?","volume":"35","author":"Demir","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib90","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000310","article-title":"Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Long","year":"2024","journal-title":"Hepatol. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib91","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cmet.2008.08.008","article-title":"Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice","volume":"8","author":"Troy","year":"2008","journal-title":"Cell. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.diabres.2014.04.008","article-title":"Intestinal glucose metabolism revisited","volume":"105","author":"Mithieux","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.phrs.2026.108444_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155329","article-title":"Study on the mechanism of modified Gegen Qinlian decoction in regulating the intestinal flora-bile acid-TGR5 axis for the treatment of type 2 diabetes mellitus based on macro genome sequencing and targeted metabonomics integration","volume":"132","author":"Liu","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phrs.2026.108444_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2026.157876","article-title":"Oligopeptides from Gynura divaricata improve glycemic control via inhibition of gluconeogenesis and gut-brain axis regulation","volume":"153","author":"Zhang","year":"2026","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib95","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40168-018-0439-y","article-title":"Microbiome-host systems interactions: protective effects of propionate upon the blood-brain barrier","volume":"6","author":"Hoyles","year":"2018","journal-title":"Microbiome"},{"issue":"10","key":"10.1016\/j.phrs.2026.108444_bib96","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease","volume":"6","author":"Rau","year":"2018","journal-title":"U. Eur. Gastroenterol. J."},{"issue":"2","key":"10.1016\/j.phrs.2026.108444_bib97","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2026.108444_bib98","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-nutr-082018-124344","article-title":"Bile Acids as Metabolic Regulators and Nutrient Sensors","volume":"39","author":"Chiang","year":"2019","journal-title":"Annu. Rev. Nutr."},{"issue":"1","key":"10.1016\/j.phrs.2026.108444_bib99","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib100","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/jcb.27635","article-title":"Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics","volume":"120","author":"Chen","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.phrs.2026.108444_bib101","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1039\/D3FO04855A","article-title":"Dynamic response of different types of gut microbiota to fructooligosaccharides and inulin","volume":"15","author":"Yin","year":"2024","journal-title":"Food Funct."},{"key":"10.1016\/j.phrs.2026.108444_bib102","article-title":"Advances in prebiotic carbohydrate-based targeted delivery: overcoming gastrointestinal challenges for bioactive ingredients","volume":"466","author":"Zhang","year":"2024","journal-title":"Food Chem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:04:51Z","timestamp":1793693091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826003592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":102,"alternative-id":["S1043661826003592"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108444","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gut microbiota modulates nonalcoholic fatty liver disease (NAFLD) progression via regulation of gluconeogenesis: mechanisms and translational research","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108444"}}